Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Table 2 Baseline WPAI scores: RAJ4

WPAI domain^a	Placebo (N=170)	Peficitinib 100 mg (N=174)	Peficitinib 150 mg (N=174)	Peficitinib 100 mg + 150 mg (N=348)	p value^b
Absenteeism^c
n	103	82	101	183	0.180
Mean (SD)	9.18 (22.43)	4.75 (11.04)	5.89 (14.78)	5.38 (13.21)	0.180
Presenteeism^c
n	99	83	101	184	0.994
Mean (SD)	43.43 (26.15)	43.01 (30.71)	43.37 (28.05)	43.21 (29.20)	0.994
Loss of work productivity^c
n	99	82	101	183	0.962
Mean (SD)	45.28 (27.03)	44.37 (30.96)	45.53 (29.13)	45.01 (29.88)	0.962
Daily activity impairment
n	169	173	173	346	0.471
Mean (SD)	52.60 (29.18)	48.84 (29.33)	50.69 (26.36)	49.77 (27.86)	0.471

SD Standard deviation, WPAI Work Productivity and Activity Impairment
^aHigher WPAI scores indicate greater work/activity impairment, expressed as percentage
^bp values calculated using analysis of covariance, with no adjustment made for multiplicity
^cOnly “full-time paid workers” and “part-time paid workers” were included (not “homemakers”)

ISSN: 1478-6362